ReviewEuropean respiratory review : an official journal of the European Respiratory Society2019
The microbiome in bronchiectasis.
Review in European respiratory review : an official journal of the European Respiratory Society, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
60 citing papers in PubMed, 1 synthesis or guideline pooled it, 148 citations in OpenAlex.
- Eradication treatment forEuropean respiratory review : an official journal of the European Respiratory Society · 2024Pooled it
- Bronchoalveolar Lavage Metagenomic Sequencing in the Early Post-Lung Transplantation Period: A Pilot Comparison with Microbiologic Culture.medRxiv : the preprint server for health sciences · 2026Article
- Study on the correlation between respiratory microbiome alterations and disease location/severity in children with Mycoplasma pneumoniae pneumonia.BMC microbiology · 2026Article
- Microbiological Analysis Following Periodontal Treatment in Individuals with Bronchiectasis.Microorganisms · 2026Article
- The Role of Cellular Senescence in Obstructive Airway Diseases: From Mechanisms to Therapeutic Targets.International journal of molecular sciences · 2026Review
- Crosstalk between the microbiome and the mucosal immunoglobulin A system in the lung, in health and disease.Frontiers in cellular and infection microbiology · 2026Review
- Pulmonary infection byFrontiers in cellular and infection microbiology · 2026Article
- Sex-Associated Radiographic and Clinical Differences in Nontuberculous Mycobacteria Pulmonary Disease.Chronic obstructive pulmonary diseases (Miami, Fla.) · 2025Article
- Risk of total and cause-specific mortality in patients with rheumatoid arthritis-associated interstitial lung disease or bronchiectasis.Rheumatology (Oxford, England) · 2025Article
- Dancing with the Dust Devil: Examining the Lung Mycobiome of Sonoran Desert Wild Mammals and the Effect ofPathogens (Basel, Switzerland) · 2025Article
- A Rare Case of Exophiala Dermatitidis Isolation in a Patient with Non-Cystic Fibrosis Bronchiectasis: Colonization or True Infection?Diagnostics (Basel, Switzerland) · 2025Article
- Review
- Short-term stability of the sputum microbiota in bronchiectasis and cystic fibrosis.ERJ open research · 2025Article
- The Respiratory Tract Microbiome and Human Health.Microbial biotechnology · 2025Review
- Sputum microbiology data and related clinical outcomes among adult Aboriginal Australians with bronchiectasis.Internal medicine journal · 2025Article
- Phenotypes and endotypes in bronchiectasis: a narrative review of progress toward precision medicine.Journal of thoracic disease · 2025Review
- Characteristics of tongue coating microbiota in diabetic and non-diabetic kidney patients receiving hemodialysis.BMC oral health · 2025Article
- The role of T-helper and T regulatory cells in driving neutrophilic and eosinophilic inflammation in bronchiectasis.Frontiers in immunology · 2025Review
- Impact of Antipseudomonal Antibiotics in Patients with Bronchiectasis Who Experienced Exacerbation or Developed Pneumonia: A Nationwide Study in Japan.Antibiotics (Basel, Switzerland) · 2024Article
- Evidence-based management guidelines for noncystic fibrosis bronchiectasis in children and adolescents.Clinical and experimental pediatrics · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Bronchiectasis is increasing in prevalence worldwide, yet current treatments available are limited to those alleviating symptoms and reducing exacerbations. The pathogenesis of the disease and the inflammatory, infective and molecular drivers of disease progression are not fully understood, making the development of novel treatments challenging. Understanding the role bacteria play in disease progression has been enhanced by the use of next-generation sequencing techniques such as 16S rRNA sequencing. The microbiome has not been extensively studied in bronchiectasis, but existing data show lung bacterial communities dominated by
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.